Literature DB >> 24411032

Evaluation of the relationship between urodynamic examination and urinary tract infection based on urinalysis results.

Shih-Wei Tsai1, Fu-Tsai Kung1, Fei-Chi Chuang1, Yu-Che Ou1, Chia-Jen Wu2, Kuan-Hui Huang3.   

Abstract

OBJECTIVE: To determine risk factors for urinary tract infection (UTI) after urodynamic examination by evaluating patients' clinical characteristics and urodynamic parameters.
MATERIALS AND METHODS: Two hundred and sixty-one female patients (mean age 58.7 ± 12.3 years) from May to December 2011 who had lower urinary tract symptoms or needed definite diagnosis before pelvic floor reconstruction or anti-incontinence surgery received urodynamic examination. All patients received urinalysis on the scheduled day of urodynamic examination and 3 days after urodynamic examination. Mid-stream urine samples were obtained for urinalysis before urodynamic examination. If patients had UTI based on our urinalysis criteria before urodynamic examination, the investigation was postponed until the patient had a 3-7-day course of antibiotic treatment and urinalysis showed no UTI.
RESULTS: Among 261 patients, 19 and 51 patients had UTI before and after urodynamic examination, respectively. Our data suggest that urodynamic examination causes significantly increased incidence of UTI. Increased number of vaginal births, UTI before investigation, diabetes and decreased average flow rate are risk factors for UTI after urodynamic examination.
CONCLUSION: When the prevalence of UTI after urodynamic examination is higher than 10%, we recommend that prophylactic antibiotics should be given for high-risk patients with parameters such as older age, diabetes and multipara (>3). Those who have UTI before urodynamic examination and who are found to have a low average flow rate of less than 7 mL/second should take prophylactic antibiotics after examination.
Copyright © 2013. Published by Elsevier B.V.

Entities:  

Keywords:  antibiotic; urinary tract infection; urodynamic study

Mesh:

Year:  2013        PMID: 24411032     DOI: 10.1016/j.tjog.2013.10.007

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  7 in total

Review 1.  Lower urinary tract symptoms in women with diabetes mellitus: a current review.

Authors:  Rebecca James; Adonis Hijaz
Journal:  Curr Urol Rep       Date:  2014-10       Impact factor: 3.092

2.  Analysis of the incidence and risk factors of male urinary tract infection following urodynamic study.

Authors:  Z Huang; H Xiao; H Li; W Yan; Z Ji
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-06-02       Impact factor: 3.267

3.  Dipstick urinalysis does not predict post-urodynamic study morbidity.

Authors:  Kasey Roberts; Anood Alfahmy; Diana Mitchell; Stacy Kamumbu; Audry Sebikali-Potts; David Sheyn
Journal:  Int Urogynecol J       Date:  2022-06-28       Impact factor: 2.894

4.  Should We Always Use Antibiotics after Urodynamic Studies in High-Risk Patients?

Authors:  Pawel Miotla; Sara Wawrysiuk; Kurt Naber; Ewa Markut-Miotla; Pawel Skorupski; Katarzyna Skorupska; Tomasz Rechberger
Journal:  Biomed Res Int       Date:  2018-11-05       Impact factor: 3.411

5.  The impact of the coronavirus disease 2019 pandemic on changes in antimicrobial prophylaxis and development of genito-urinary tract infections after urodynamic study: A retrospective comparative study of a single rehabilitation hospital in Japan.

Authors:  Shigeto Mukai; Masashi Nomi; Sae Kozawa; Akihiro Yanagiuchi; Katsumi Shigemura; Atsushi Sengoku
Journal:  Neurourol Urodyn       Date:  2022-06-08       Impact factor: 2.367

6.  Rate of urinary tract infection after urodynamic study in pelvic floor clinic.

Authors:  Zinat Ghanbari; Fedyeh Haghollahi; Tahere Eftekhr; Tahere Froghifar; Mamak Shariat; Maryam Hajihashemy; Mohsen Ayati
Journal:  Caspian J Intern Med       Date:  2020

Review 7.  Antibiotic prophylaxis for urodynamic testing in women: a systematic review.

Authors:  Anouk Benseler; Breffini Anglim; Zi Ying Zhao; Chris Walsh; Colleen D McDermott
Journal:  Int Urogynecol J       Date:  2020-08-26       Impact factor: 2.894

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.